Edition:
United States

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

1.44USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
48,992
52-wk High
$15.50
52-wk Low
$1.28

Latest Key Developments (Source: Significant Developments)

Diffusion Pharmaceuticals reports qtrly net income per diluted share $0.20‍​
Monday, 13 Nov 2017 06:41am EST 

Nov 13 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals Inc qtrly net income per diluted share $0.20‍​.Diffusion Pharmaceuticals Inc - ‍remain on track to begin enrolling patients by end of 2017 for tsc glioblastoma phase 3 pivotal study​.Diffusion Pharmaceuticals Inc - ‍awaiting confirmation from Nasdaq that co demonstrated compliance with all applicable requirements for continued listing​.  Full Article

Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme.Has responded to all outstanding points raised by FDA, plans to begin trial under protocol agreed to by FDA by end of 2017​.Trial to compare survival at 2 yrs of patients receiving TSC concurrent with chemo, radiation with patients receiving SOC alone​.  Full Article

Diffusion Pharmaceuticals Q2 loss per share $1.00
Monday, 14 Aug 2017 04:01pm EDT 

Aug 14 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals reports second quarter 2017 financial results and provides business update.Qtrly loss per share $1.00.  Full Article

Diffusion Pharma achieves drug production milestone
Thursday, 20 Jul 2017 08:30am EDT 

July 20 (Reuters) - Diffusion Pharmaceuticals Inc ::Diffusion Pharmaceuticals achieves drug production milestone for planned phase 3 clinical trial in inoperable GBM brain cancer.Says ‍diffusion plans to initiate this clinical trial by end of 2017​.Diffusion Pharmaceuticals- interacting with FDA regarding design, execution of planned phase 3 study, with initiation planned for later this year​.Diffusion-Planned studies include phase 2 trials in pancreatic cancer, brain metastases; initiation subject to receipt of funding/collaborative partnering.  Full Article

Diffusion Pharmaceuticals files for offering up to 26.5 mln shares
Wednesday, 17 May 2017 05:16pm EDT 

May 17 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals Inc files for offering up to 26.5 million shares of common stock by the selling stockholders - SEC filing.  Full Article

Diffusion Pharmaceuticals Q1 net loss was $28.6 million
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Diffusion Pharmaceuticals Inc ::Diffusion Pharmaceuticals provides corporate highlights and reports financial first quarter 2017 results.Net loss was $28.6 million for three months ended March 31, 2017, compared to a net loss of $6.2 million.  Full Article

Diffusion Pharmaceuticals Q3 loss per share $0.53
Monday, 14 Nov 2016 08:00am EST 

Diffusion Pharmaceuticals Inc : Diffusion pharmaceuticals provides corporate highlights and reports financial third quarter 2016 results .Q3 loss per share $0.53.  Full Article

Diffusion Pharmaceuticals reports first quarter 2016 results
Monday, 16 May 2016 04:16pm EDT 

Diffusion Pharmaceuticals Inc :Diffusion pharmaceuticals provides corporate highlights and reports first quarter 2016 results.  Full Article

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme